Study Objectives: Each year, there are approximately 1 million cases of deep venous thrombosis (DVT) and 700,000 hospital admissions in the United States. Patients seen in the emergency department (ED) have traditionally been admitted to the hospital to start on anti-coagulation therapy. However, with the emergence of novel oral anticoagulants, there has been growing evidence that selected patients can be optimally managed in the outpatient setting. Due to logistic and financial concerns, there is typically a significant delay in adopting new treatment algorithms in the community hospital setting. By locally deriving a DVT management protocol with attention to its disposition and financial consequences, we hoped to overcome these barriers to adoption. The primary objectives of this study were to develop a standardized protocol to manage the newly diagnosed uncomplicated lower extremity DVT and to describe its potential impact on emergency department disposition and hospital reimbursement.
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Methods: From May 1 st , 2017 to April 30 th , 2018, we conducted a 2-phased study designed to evaluate the impact of a standardized lower extremity DVT treatment protocol at a large suburban 95,000 visit community hospital. The first phase of the study involved developing a standardized DVT treatment protocol. A multidisciplinary team was tasked with creating a protocol incorporating a combination of guidelines from American College of Chest Physicians and the Michigan Quality Improvement Consortium. Special attention was given to culture and logistics of our institution. In the second phase of our study, we retrospectively applied the protocol to all ED patients seen at our institution in 2015 who were diagnosed with an uncomplicated lower extremity DVT. Our primary outcome was to examine the difference in final disposition between patients receiving standard of care versus undergoing protocol implementation. Our secondary outcome was to describe the effect on hospital reimbursement across both cohorts. Data was analyzed using descriptive statistics.
Results: In 2015, a total of 273 patients met the inclusion criteria of uncomplicated lower extremity DVT at our institution. The initial cohort was comprised of 3 groups: 1) Inpatient admission [INP] , 2) Outpatient admission [OUT] , and 3) Discharge from ED [DIS] . New disposition results after application of our protocol are seen in Figure #1 . 24/ 192 (12.5%) of INP would have been discharged under our protocol. As the protocol did not utilize an observation cohort, 14/27 (51.9%) in the OUT cohort would have been discharged, while 13/27 (48.1%) would have been admitted. In the DIS group, 22/67 (32.8%) should have been admitted if our guideline had been used. Hospital reimbursement per case averages for primary DVT diagnosis in 2015 were obtained.
Applying our protocol would have incurred a total gain of $65,571 in total charges, resulting in $23,883 dollars of net profit after direct costs.
Conclusions: Development of a locally derived DVT management protocol can align all incentives by optimizing treatment, increasing discharges and increasing reimbursement. Study Objectives: Outpatient management for patients presenting to the emergency department (ED) with acute deep venous thrombosis (DVT) has been shown to be safe. However, many patients have neither access to outpatient care nor can afford costly direct oral anticoagulant medications. We developed an ED clinical pathway which aims to improve access issues for all patients presenting with an acute DVT. This is the first such pathway which uses apixaban to these authors' knowledge. Objectives include safely decreasing hospital admissions; reducing downstream readmissions; and increasing outpatient follow-up.
Methods: We developed an acute DVT clinical pathway. ED providers prescribed apixaban to patients eligible for discharge. ED pharmacists provided medication counseling and free 30-day vouchers. Case managers arranged outpatient appointments and provided financial aid guidance for apixaban treatment beyond 30 days for underinsured patients. For iliofemoral DVTs, interventional radiologists were consulted for consideration of intravascular therapy. ED providers were educated on the clinical pathway December 2016, and it was implemented January 2017. Charts were reviewed from 6 months pre-and post-implementation. Primary outcomes included discharge and outpatient follow-up rates. Secondary outcomes included repeat ED visit and hospitalization rates for DVT-related illness following discharge. Only patients with acute DVT diagnosed on formal Doppler ultrasound were included. Dichotomous variables were compared using the Fisher Exact Test.
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